張佩靖特聘教授
- 微生物及免疫學研究所 特聘教授
- 專長領域: 表觀基因體學、病毒學、細胞自噬、癌症研究
- 辦公室位置: 生物醫學大樓(R306)
- TEL (辦公室): +886-2-28267111
- TEL (實驗室): +886-2-28267000 ext 65617
- E-mail: pcchang@nycu.edu.tw
- ORCID: 0000-0001-8665-5494
學歷
國立陽明大學 藥理學研究所碩士
國立陽明大學 生化暨分子生物研究所博士
University of Kentucky博士後研究員
UC Davis博士後研究員
經歷
國立陽明大學微生物及免疫學研究所 特聘教授 (2021~迄今)
Lerner Research Institute, Cleveland Clinic訪問學者 (2021~迄今)
國立陽明大學微生物及免疫學研究所 教授 (2020~迄今)
國立陽明大學微生物及免疫學研究所 副教授 (2016~2020)
高雄醫學大學傳染病與癌症研究中心 副研究員 (2016~2019)
University of South California (USC), School of Pharmacy 訪問學者 (2015~2016)
國立陽明大學 微生物及免疫學研究所 助理教授 (2011~2016)
獲獎榮譽
國立陽明交通大學資深優良教師 (110學年度)
國立陽明交通大學生命科學院第二季重要期刊論文 (110學年度)
國立陽明交通大學生命科學院第二季重要期刊論文 (109學年度)
國立陽明交通大學醫學系良師益友 (108學年度)
醫學系網路教學評量 優良教師獎狀 (105-109學年度)
醫學系網路教學評量 優良教師琉璃獎座 (103學年度)
國立陽明交通大學生命科學系良師益友導師獎 (102學年度)
醫學系網路教學評量 優良教師獎狀 (101-102學年度)
論文
-
S. Yang, W.W. Yeh, M. Campbell, L. Chang, P.C. Chang* “Long non-coding RNA KIKAT/LINC01061 as a novel epigenetic regulator that relocates KDM4A on chromatin and modulates viral reactivation” PLoS Pathogens 2021; 17((6)):e1009670 (SCI). (Impact factor: 6.218; Rank: 6.76%) 通訊作者
-
Campbell, W.S. Yang, W.W. Yeh, C.H. Kao, P.C. Chang* “Epigenetic Regulation of Kaposi’s sarcoma-associated herpesvirus Latency” Frontiers in Microbiology 2020; 19(11):850 (SCI). (Impact factor: 5.640Rank: 24.63%) 通訊作者
-
W. Liang, M.L. Wang, C.H. Chien, Y.P. Yang, A.A. Yarmishyn, W.Y. Lai, Y.H. Luo, Y.T. Lin, P.C. Chang*, S.H. Chiou* “Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection” Frontiers in Immunology 2020; 12(11):1022 (SCI). (Impact factor: 7.561;Rank: 24.21%) 共同通訊作者
-
C. Tsai, W.H. Chiang, C.H. Wu, Y.C. Li, M. Campbell, P.H. Huang, M.W. Lin, C.H. Lin, S.M. Cheng, P.C. Chang*, C.C. Cheng “miR-548aq-3p is a novel target of Far infrared radiation which predicts coronary artery disease endothelial colony forming cell responsiveness” Scientific Reports 2020; 10((1)):6805 (SCI). (Impact factor: 4.380; Rank: 23.24%) 通訊作者
-
P. Yang, W.S. Yang, Y.H. Wong, K.H. Wang, Y.C. Teng, M.H. Chang, K.H. Liao, F.S. Nian, C.C. Chao, JW Tsai, W.L. Hwang, M.W. Lin, T.Y. Tzeng, P.N. Wang, M. Campbell, L.K. Chen, T.F. Tsai, P.C. Chang*, H.J. Kung “Muscle atrophy-related myotube-derived exosomal microRNA in neuronal dysfunction: Targeting both coding and long noncoding RNAs” AGING CELL 2020; 19((5)):e13107 (SCI). (Impact factor: 7.238;Rank: 4.90%) 通訊作者
-
S. Yang, T.Y. Lin, L. Chang, W.W. Yeh, S.C. Huang, T.Y. Chen, Y.T. Hsieh, S.T. Chen, W.C. Li, C.C. Pan, M. Campbell, C.H. Yen, Y.A. Chen, P.C. Chang* “HIV-1 Tat Interacts with a Kaposi’s Sarcoma-Associated Herpesvirus Reactivation-Upregulated Antiangiogenic Long Noncoding RNA, LINC00313, and Antagonizes Its Function” JOURNAL OF VIROLOGY 2020; 94(3):e01280-19 (SCI). (Impact factor: 4.501;Rank: 20.27%) 通訊作者
-
J. Lin, L. Chang, H.W. Chu, H.J. Lin, P.C. Chang, R.Y.L. Wang, B. Unnikrishnan, J.Y. Mao, S.Y. Chen, C.C. Huang “High Amplification of the Antiviral Activity of Curcumin through Transformation into Carbon Quantum Dots” Small 2019; 15(41):e1902641 (SCI). (Impact factor: 11.459;Rank: 6.13%) 第五作者
-
Kant, C.H. Yen, J.H. Hung, C.K. Lu, C.Y. Tung, P.C. Chang, Y.H. Chen, Y.C. Tyan, Y.A. Chen “Induction of GNMT by 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside through proteasome-independent MYC downregulation in hepatocellular carcinoma” Scientific Reports 2019; 9(1):1968 (SCI). (Impact factor: 3.998;Rank: 23.24%) 第六作者
-
T. Chang, T.P. Lin, J.T. Tang, M. Campbell, Y.L. Luo, S.Y. Lu, C.P. Yang, T.Y. Cheng, C.H. Chang, T.T. Liu, C.H. Lin, H.J. Kung, C.C. Pan, P.C. Chang* “HOTAIR is a REST-regulated LncRNA that Promotes Neuroendocrine Differentiation in Castration Resistant Prostate Cancer” CANCER LETTERS 2018; 433:43-52 (SCI). (Impact factor: 7.36;Rank: 12.09%) 通訊作者
-
S. Yang, M. Campbell, H.J. Kung, P.C. Chang* “In vitro SUMOylation Assay to Study SUMO E3 Ligase Activity” Jove-Journal of Visualized Experiments 2018; 131(e56629):1-6 (SCI). (Impact factor: 1.163;Rank: 62.68%) 通訊作者
-
C. Lin, Y.T. Chang, M. Campbell, H.C. Lee, J. C. Shih, P.C. Chang* “MAOA- a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells” Scientific Reports 2017; 7:46338 (SCI). (Impact factor: 3.998;Rank: 23.24%) 通訊作者
-
H. Liu, J.W. Tsai, J.L. Chen, W.S. Yang, P.C. Chang, P.L. Cheng, D.L. Turner, Y. Yanagawa, T.W. Wang, J.Y. Yu “Ascl1 promotes tangential migration and confines migratory routes by induction of Ephb2 in the telencephalon.” Scientific Reports 2017; 7(42895):1 (SCI). (Impact factor: 3.998;Rank: 23.24%) 第五作者
-
T. Chang, T.P Lin, M. Campbell, C.C. Pan, S.H. Lee, H.C. Lee, M.H. Yang, H.J. Kung, P.C. Chang* “REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer” Scientific Reports 2017; 3(7):42795 (SCI). (Impact factor: 3.998;Rank: 23.24%) 通訊作者
-
W.S.Yang, M. Campbell, P.C. Chang* ”SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.” PLoS Pathogens 2017; 13(2):e1006216 (SCI). (Impact factor: 6.218;Rank: 6.76%) 通訊作者
-
C. Chang*, M. Campbell, E.S. Robertson “Human Oncogenic Herpesvirus and Post-translational Modifications – Phosphorylation and SUMOylation” Frontiers in Microbiology 2016; 7: (SCI). (Impact factor: 4.236;Rank: 24.63%) 第一作者/通訊作者
-
P. Lin, Y.T. Chang, S.Y. Lee, M. Campbell, T.C. Wang, S.H. Shen, H.J. Chung, Y.H. Chang, Allen W Chiu, C.C. Pan, C.H. Lin, C.Y. Chu, H.J. Kung, C.Y. Cheng, P.C. Chang. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget 2016; 7:26137~26151 (SCI). (Impact factor: 5.168;Rank: 20.05%) 通訊作者
-
S. Yang, H.W. Hsu, M. Campbell, C.Y. Cheng, P.C. Chang* “K-bZIP mediated SUMO-2/3 specific modification on the KSHV genome negatively regulates lytic gene expression and viral reactivation” PLoS Pathogens 2015; 11(7): (SCI). (Impact factor: 6.218;Rank: 6.76%) 通訊作者
-
C. Chang* and H.J. Kung “SUMO and KSHV Replication” CANCER 2014; 6(4):1905-1924 (SCI). (Impact factor: 5.772;Rank: 18.65%) 第一作者/通訊作者
-
C. Chang*, T.Y. Wang, Y.T. Chang, C.Y. Chu, C.L. Lee, H.W. Hsu, T.A. Zhou, Z. Wu, R.H. Kim, S.J. Desai, S. Liu, H.J. Kung “Autophagy Pathway Is Required for IL-6 Induced Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells” PLoS ONE 2014; 9:e88556 (SCI). (Impact factor: 2.74;Rank: 37.32%) 第一作者/通訊作者
-
M. Campbell, K.Y. Kim, P.C. Chang, S. Huerta, B. Shevchenko, D.H. Wang, C. Izumiya, H.J. Kung, Y. Izumiya “A Lytic Viral Long Non-coding RNA Modulates the Function of a Latent Protein” Journal of Virology 2014; 88(3):1843~1848 (SCI). (Impact factor: 4.501;Rank: 20.27%) 第三作者
-
Y. Cheng, C.H. Chu, H.W. Hsu, F.R. Hsu, C.Y. Tang, W.C. Wang, H.J. Kung, P.C. Chang* “An improved ChIP-seq peak detection system for simultaneously identifying post-translational modified transcription factors by combinatorial fusion, using SUMOylation as an example” BMC genomics 2014; 15:S1 (SCI). (Impact factor: 3.594;Rank: 27.24%) 通訊作者
-
C. Chang*, C.Y. Cheng, M. Campbell, Y.C. Yang, H.W. Hsu, T.Y. Chang, C.H. Chu, Y.W. Lee, C.L. Hung, S.M. Lai, C.G. Tepper, W.P. Hsieh, H.W. Wang, C.Y. Tang, W.C. Wang, H.J. Kung “The chromatin modification by SUMO-2/3 but not SUMO-1 prevents the epigenetic activation of key immune-related genes during Kaposi’s sarcoma associated herpesvirus reactivation.” BMC Genomics 2013; 14(1):824 (SCI). (Impact factor: 3.594;Rank: 27.24%) 第一作者/通訊作者
-
M. Campbell, P.C. Chang, S. Huerta, C. Izumiya, R. Davis, C.G. Tepper, K.Y. Kim, B. Shevchenko, D.H. Wang, J.U. Jung, P.A. Luciw, H.J. Kung, Y. Izumiya “Protein Arginine Methyltransferase 1-directed Methylation of Kaposi Sarcoma-associated Herpesvirus Latency-associated Nuclear Antigen” JOURNAL OF BIOLOGICAL CHEMISTRY 2012; 287(8):5806–5818 (SCI). (Impact factor: 4.238;Rank: 29.13%) 第二作者
-
P.C. Chang*, Y. Izumiya, C.Y. Wu, L.D. Fitzgerald, M. Campbell, T. Ellison, K.S. Lam, P.A. Luciw, H.J. Kung “Histone demethylase JMJD2A regulates Kaposi’s sarcoma-associated herpesvirus replication and is targeted by a viral transcriptional factor” JOURNAL OF VIROLOGY 2011; 85(7):3283-3293 (SCI). (Impact factor: 4.501;Rank: 20.27%) 第一作者
-
P.C. Chang*, L.D. Fitzgerald, D.A. Hsia, Y. Izumiya, C.Y. Wu, W.P. Hsieh, S.F. Lin, M. Campbell, K.S. Lam, P.A. Luciw, C.G. Tepper, H.J. “Kaposi’s sarcoma associated herpesvirus (KSHV) encodes a SUMO E3 ligase which is SIM-dependent and SUMO-2/3-specific” JOURNAL OF BIOLOGICAL CHEMISTRY 2010; 285(8):5266-5273 (SCI). (Impact factor: 4.238;Rank: 29.13%) 第一作者
-
Z. Wu, P.C. Chang, J. Yang, C.Y. Chu, L.Y. Wang, N.T. Chen, A.H. Ma, S.J. Desai, S.H. Lo, C.P. Evans, K.S. Lam, and H.J. Kung “Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors” Genes & Cancer 2010; 1(1):40-49 (SCI). 第二作者
-
P.C. Chang*, L. Fitzgerald, A. Van Geelen, Y. Izumiya, T.J. Ellison, D.H. Wang, D.K. Ann, P.A. Luciw, H.J. Kung “KRAB domain-associated protein-1 as a latency regulator for Kaposi’s sarcoma-associated herpesvirus and its modulation by the viral protein kinase” CANCER RESEARCH 2009; 69(14):5681-5689 (SCI). (Impact factor: 9.727;Rank: 7.58%) 第一作者
-
Y.L. Lin, P.C. Chang, Y. Wang, and M. Li “Identification of novel viral interleukin-10 isoforms of human cytomegalovirus AD169” VIRUS RESEARCH 2008; 131(2):213-223 (SCI). (Impact factor: 2.934;Rank: 47.30%) 第二作者
-
P. C. Chang* and M. Li “Kaposi’s sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor” JOURNAL OF VIROLOGY 2008; 82(1):278-290 (SCI). (Impact factor: 4.501;Rank: 20.27%) 第一作者
-
P. C. Chang*, C.W. Chi, G.Y. Chau, F.Y. Li, Y.H. Tsai, J.C. Wu and Y.H.W. Lee “DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus associated hepatocellular carcinoma and is involved in cell growth control” ONCOGENE 2006; 25(14):1991-2003 (SCI). (Impact factor: 7.971;Rank: 7.58%) 第一作者
-
F. Chiou, P.C. Chang, C.I. Chou, C.F. Chen “Protein constituent contributes to the hypotensive and vasorelaxant activities of Cordyceps Sinensis ” LIFE SCIENCES 2000; 66(14):1369-1376 (SCI). (Impact factor: 3.647;Rank: 27.86%) 第二作者
計畫
1.Investigation of the mechanism and medical implications of a novel histone lysine demethylase KDM4A interacting long non-coding RNAs (LncRNAs) LINC01061 in viral reactivation and tumorigenesis [探討組蛋白去甲基酶 KDM4A 結合長鏈非編碼RNA (lncRNAs) LINC01061 參與病毒活化與細胞癌化的機制及其醫療角色(111-113)], PI, 2022/01/01-2024/12/31, National Health Research Institutes (NHRI-EX111-11125BI; 3 years)
2.Epigenetic regulation of IL-10 production in virus induced B-lymphocyte in modulation host inflammatory response and cell pathogenesis [探討病毒誘發B淋巴細胞生成IL-10之表關基因體調控及調節宿主細胞之發炎反應(1/2~2/2)], PI, 202107-201312, Ministry of Science and Technology (MOST) (109-2926-I-010-503 -, *** ; 2 years) — 與CCF合作計畫
3.Using KSHV reactivation as a model to identify oncogenic long non-coding RNAs (LncRNAs) and elucidate their role in epigenetic regulation of human cancer [利用致癌性卡波氏肉瘤相關性皰疹病毒當研究模式 尋找癌化相關之長鏈非編碼RNA並探討其在表觀遺傳性腫瘤發生過程中所扮演的角色], PI, 2019/08/01-2022/07/31, Ministry of Science and Technology (MOST) (108-2320-B-010-029-MY3; 3 years)
4.Using KSHV as a model to study the role of SUMOylation in regulating the chromatin remodeling mediated transcription regulation and oncogenic characteristic of JMJD2A [利用卡波西肉瘤相關性皰疹病毒當作實驗模式:探討SUMO修飾組織蛋白去甲基酶JMJD2A對其附基因體調控基因表現與細胞癌化能力之影響] PI, 20160801-20190731, Ministry of Science and Technology (MOST) (105-2320-B-010-007-MY3; 3 years)
5.The role of REST in epigenetic regulation of neuroendocrine cancer stem cell-mediated chemoresistence [REST所調控之附基因體轉化對神經內分泌分化癌症幹細胞導致之攝護腺癌化療機制之研究], PI, 20150801-20160731, Ministry of Science and Technology (MOST) (104-2320-B-010-038-; 1 year)
6.MAO A mediates REST action on neuroendocrine differentiation and autophagy activation of prostate cancer relapse [MAO A 在復發型攝護腺癌中REST造成之癌細胞神經內分泌樣分化與自噬機制活化中所扮演的角色((1/2~2/2)], PI, 20160101~20170331, Ministry of Science and Technology (MOST) (103-2911-I-010-515 -, 104-2911-I-010-505 ; 2 years) — 與USC合作計畫
7.SUMO and KSHV: Epigenetic regulation of Oncogenic Herpesvirus [SUMO與卡波西肉瘤相關皰疹 病毒:附基金體調控致癌性病毒皰疹(102-105)], PI, 20130101-20161231, National Health Research Institutes (NHRI-EX105-10215BC; 4 year)
8.The role of SUMO-2/3 in epigenetic regulation of herpesvirus: Implication in developing novel SUMO-2/3 target therapy [附基因體模式探討SUMO-2/3 調控疱疹病毒的生長與致病機制: 發展SUMO-2/3專一性標靶藥物(1/3~3/3)], PI, 20120801~20150731, National Science Council (NSC) (101-2321-B-010-017-; 102-2321-B-010-015-; 103-2321-B-010-006-; 3 years)
9.Autophagy, neuroendocrine differentiation and prostate cancer therapeutic resistance [細胞自噬機制在神經內分泌分化導致之抗攝護腺癌治療作用之探討], PI, 20120801~20150731, National Science Council (NSC) (101-2320-B-010-047-MY3; 3 years).
實驗室介紹
(I) Virus-Host interaction: Epigenetic regulation and Cancer
Epigenetic regulation includes: (1) DNA methylation; (2) Histone methylation and (3) Long non-coding RNAs (LncRNAs). By using oncogenic herpesvirus KSHV as a model, we studied the tumorigenic role of JMJD2A, the first identified histone trimethyl demethylase, and its own modification in epigenetic regulation. We found that JMJD2A is important for maintain low levels of H3K9me3, a favorable chromatin environment to execute rapid transcriptional reprograming. JMJD2A was targeted and sumoylated by KSHV K-bZIP, a viral SUMO E3 ligase. Sumoylation is essential for chromatin binding and in vivo dementylation function of JMJD2A. Our study also showed the role of JMJD2A in regulating IFN response and how virus against human immune system through targeting JMJD2A. Nowadays, we use KSHV as a model to identify novel KSHV reactivation associated long non-coding RNAs (lncRNAs), a newly emerged epigenetic regulator, and elucidate their tumorigenic role.
(II) Epigenetic regulation of Prostate Cancer
I further extend our epigenetic study to prostate cancer (PCa) research. PCa is a leading cancer affecting male population. Thought it can be successful treated by androgen deprivation therapy (ADT), unfortunately, hormone refractory prostate cancer (HRPC) eventually relapsed within few years after successful treatment. Thought 2nd generation of AR antagonist was developed and used for treating HRPC, it induced neuroendocrine differentiation (NED) of PCa cells. This emerging type of PCa, so-called NEPC, is highly metastatic and chemoresistant. We identified repressor element-1 (RE-1) silencing transcription factor (REST) as a key regulator for. Following this observation, we also demonstrated that long-term REST knockdown not only induce NED but also enhanced cell stemness through epigenetic regulation of Twist1 and CD44. In addition, we identified MAOA, a decision maker of apoptosis (inhibition) and autophagy (activation), as a novel REST target gene. It involves in mediating mitophagy activation during NED of PCa cells. Nowadays, we use NED as a model and identified many novel NED regulatory lncRNAs, including HOTAIR.
(III) Cancer Immunology
Emerging evidence showed that microenvironment shaped by pro- and anti-inflammatory types of macrophages contribute to not only host defense, but also cancer progression. We found that cancer stem cells (CSCs), without affect macrophage phenotype, induce M1 macrophages producing NED-related cytokines. Integrating transcriptome profiling in combine with mass spectrometry metabolites analysis reveals the contribution of glycolysis pathway in NED-related cytokines production. Importantly, CSC-educated M1 macrophages induced NED of cancer cells, thereby shifting carcinoma reprograming toward a neuroendocrine (NE) fate. In tumor tissues, NE marker CgA expression is associated with M1, but not M2, marker. These findings offer therapeutic opportunities of using immunotherapy to prevent the induction of a more malignant cancer phenotype.
現在成員
2015/09 張景欣 博士生
2020/09 胡則勻 碩士生
2020/09 陳柏安 碩士生
2021/09 洪靖幃 碩士生
2021/09 鄭裕弘 碩士生
畢業博士生
2014/09張怡婷
-
C. Chang, T.Y. Wang, Y.T. Chang, C.Y. Chu, C.L. Lee, H.W. Hsu, T.A. Zhou, Z. Wu, R.H. Kim, S.J. Desai, S. Liu, H.J. Kung “Autophagy Pathway Is Required for IL-6 Induced Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells” PLoS ONE 2014; 9:e88556 (SCI). (Impact factor: 2.74;Rank: 37.32%)
-
P. Lin, Y.T. Chang, S.Y. Lee, M. Campbell, T.C. Wang, S.H. Shen, H.J. Chung, Y.H. Chang, Allen W Chiu, C.C. Pan, C.H. Lin, C.Y. Chu, H.J. Kung, C.Y. Cheng, P.C. Chang. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget 2016; 7:26137~26151 (SCI).
-
T. Chang, T.P Lin, M. Campbell, C.C. Pan, S.H. Lee, H.C. Lee, M.H. Yang, H.J. Kung, P.C. Chang “REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer” Scientific Reports 2017; 3(7):42795 (SCI). (Impact factor: 3.998;Rank: 23.24%) [第一作者]
-
C. Lin, Y.T. Chang, M. Campbell, H.C. Lee, J. C. Shih, P.C. Chang “MAOA- a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells” Scientific Reports 2017; 7:46338 (SCI). (Impact factor: 3.998;Rank: 23.24%) [第一作者]
-
T. Chang, T.P. Lin, J.T. Tang, M. Campbell, Y.L. Luo, S.Y. Lu, C.P. Yang, T.Y. Cheng, C.H. Chang, T.T. Liu, C.H. Lin, H.J. Kung, C.C. Pan, P.C. Chang “HOTAIR is a REST-regulated LncRNA that Promotes Neuroendocrine Differentiation in Castration Resistant Prostate Cancer” Cancer Letters 2018; 433:43-52 (SCI). (Impact factor: 7.36;Rank: 12.09%) [第一作者]
2015/09 楊宛珊 (現職: Lerner Research Institute, Cleveland Clinic 博士後研究員)
-
S. Yang, W.W. Yeh, M. Campbell, L. Chang, P.C. Chang “Long non-coding RNA KIKAT/LINC01061 as a novel epigenetic regulator that relocates KDM4A on chromatin and modulates viral reactivation” PLoS Pathogens 2021; 17((6)):e1009670 (SCI). (Impact factor: 6.218; Rank: 6.76%) [第一作者]
-
Campbell, W.S. Yang, W.W. Yeh, C.H. Kao, P.C. Chang “Epigenetic Regulation of Kaposi’s sarcoma-associated herpesvirus Latency” Frontiers in Microbiology 2020; 19(11):850 (SCI). (Impact factor: 5.640Rank: 24.63%)
-
P. Yang, W.S. Yang, Y.H. Wong, K.H. Wang, Y.C. Teng, M.H. Chang, K.H. Liao, F.S. Nian, C.C. Chao, JW Tsai, W.L. Hwang, M.W. Lin, T.Y. Tzeng, P.N. Wang, M. Campbell, L.K. Chen, T.F. Tsai, P.C. Chang, H.J. Kung “Muscle atrophy-related myotube-derived exosomal microRNA in neuronal dysfunction: Targeting both coding and long noncoding RNAs Aging Cell 2020; 19((5)):e13107 (SCI). (Impact factor: 7.238;Rank: 4.90%) [第一作者]
-
S. Yang, T.Y. Lin, L. Chang, W.W. Yeh, S.C. Huang, T.Y. Chen, Y.T. Hsieh, S.T. Chen, W.C. Li, C.C. Pan, M. Campbell, C.H. Yen, Y.A. Chen, P.C. Chang* “HIV-1 Tat Interacts with a Kaposi’s Sarcoma-Associated Herpesvirus Reactivation-Upregulated Antiangiogenic Long Noncoding RNA, LINC00313, and Antagonizes Its Function” Journal of Virology 2020; 94(3):e01280-19 (SCI). (Impact factor: 4.501;Rank: 20.27%) [第一作者]
-
S. Yang, M. Campbell, H.J. Kung, P.C. Chang “In vitro SUMOylation Assay to Study SUMO E3 Ligase Activity” JoVE-Journal of Visualized Experiments 2018; 131(e56629):1-6 (SCI). (Impact factor: 1.163;Rank: 62.68%) [第一作者]
-
H. Liu, J.W. Tsai, J.L. Chen, W.S. Yang, P.C. Chang, P.L. Cheng, D.L. Turner, Y. Yanagawa, T.W. Wang, J.Y. Yu “Ascl1 promotes tangential migration and confines migratory routes by induction of Ephb2 in the telencephalon.” Scientific Reports 2017; 7(42895):1 (SCI). (Impact factor: 3.998;Rank: 23.24%)
-
S. Yang, H.W. Hsu, M. Campbell, C.Y. Cheng, P.C. Chang “K-bZIP mediated SUMO-2/3 specific modification on the KSHV genome negatively regulates lytic gene expression and viral reactivation” PLoS Pathogens 2015; 11(7): (SCI). (Impact factor: 6.218;Rank: 6.76%) [第一作者]
2016/09 張龍
-
J. Lin, L. Chang, H.W. Chu, H.J. Lin, P.C. Chang, R.Y.L. Wang, B. Unnikrishnan, J.Y. Mao, S.Y. Chen, C.C. Huang “High Amplification of the Antiviral Activity of Curcumin through Transformation into Carbon Quantum Dots” Small 2019; 15(41):e1902641 (SCI). (Impact factor: 11.459;Rank: 6.13%) [第一作者]
畢業碩士生
2011/09 張怡婷 (論文發表: PLoS One. 2014 Feb 14; 9(2):e88556)
2011/09 楊奕程 (論文發表: BMC Genomics. 2013 Nov 23; 14:824)
2013/09 楊宛珊 (論文發表: PLoS Pathog. 2015 Jul 21; 11(7):e1005051)
2013/09 李松遠 (論文發表: Oncotarget. 2016 May 3; 7(18):26137)
2015/09 羅勻里
2015/09 黃詩晴 (論文發表: J Virol. 2020 Jan 17;94(3) pii: e01280-19)
2016/09 楊佳蓓 (論文發表: Aging cell. 2020 Mar 31:e13107 )
2016/09 李悅誠
2017/09 林庭宇 (論文發表: J Virol. 2020 Jan 17;94(3) pii: e01280-19)
2017/09 江玟慧 (論文發表: Sci Rep. 2020 Apr 22;10(1):6805)
2017/09鄭庭伃
2017/09葉葳
2017/09施文仁
2018/09高晨媗
2019/09沈彩文
實驗室照片
